Area of research
Epidemiology · Pathology and Forensic Medicine
Research interest
We study immune signaling pathways to understand the role of innate immune cells in liver diseases. Our studies focus on molecular mechanisms of inflammation and immune signaling in the intestine, liver and brain in animal models and in patients with chronic liver diseases. Our recent interest is in the role of extracellular vesicles and microRNAs in cell-to cell and inter-organ communication and in biomarker discovery. We aim to discover new pathways that can be targeted to develop new therapies in alcohol- or metabolic syndrome- related organ damage using state-of-the-art approaches in translational research.
Acute-on-chronic liver failure (ACLF): the ‘Kyoto Consensus’—steps from Asia
Immunological mechanisms and emerging therapeutic targets in alcohol-associated liver disease
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease
Metabolic dysfunction and alcohol-associated liver disease (MetALD)
A single-nucleus and spatial transcriptomic atlas of the COVID-19 liver reveals topological, functional, and regenerative organ disruption in patients
Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation
Prolonged hypoxia alleviates prolyl hydroxylation-mediated suppression of RIPK1 to promote necroptosis and inflammation
Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis
Transcriptional regulation of Acsl1 by CHREBP and NF-kappa B in macrophages during hyperglycemia and inflammation
COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets
Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction
Role of the Inflammasome in Liver Disease
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Immunopathobiology and therapeutic targets related to cytokines in liver diseases
Provider Attitudes and Practices for Alcohol Screening, Treatment, and Education in Patients With Liver Disease: A Survey From the American Association for the Study of Liver Diseases Alcohol-Associated Liver Disease Special Interest Group
Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases
Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting
Acute‐on‐Chronic Liver Failure: Getting Ready for Prime Time?
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia
Human Monoclonal Antibody MBL-HCV1 Delays HCV Viral Rebound Following Liver Transplantation: A Randomized Controlled Study